Pluristem Therapeutics (NASDAQ:PSTI) issued its quarterly earnings results on Sunday. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.06), Fidelity Earnings reports.
NASDAQ:PSTI traded down $0.05 during mid-day trading on Tuesday, reaching $2.93. The stock had a trading volume of 180,556 shares, compared to its average volume of 489,636. Pluristem Therapeutics has a twelve month low of $2.81 and a twelve month high of $11.85. The business has a 50 day simple moving average of $3.26 and a 200 day simple moving average of $4.02.
An institutional investor recently raised its position in Pluristem Therapeutics stock. Morgan Stanley lifted its holdings in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 301.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,646 shares of the biotechnology company’s stock after buying an additional 44,779 shares during the quarter. Morgan Stanley owned 0.19% of Pluristem Therapeutics worth $285,000 as of its most recent SEC filing. 14.23% of the stock is owned by institutional investors.
About Pluristem Therapeutics
Pluristem Therapeutics, Inc is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies.
Read More: High-Yield Dividend Stocks
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.